Table 5.
Platelet-rich plasma (PRP) compared with control intervention as adjunct treatment for arthroscopy.
| LOE | Type of Study | Exp | Cont | Follow-up | Control | Preparation Kit | LR/LP | Platelet Concentration | Number of Inj. | PROM | Ref. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duif et al. | II | 2 arms | 24(21) | 34(32) | 12 months | no injection | ACP (Arthrex) | LP | N/R | 1 | VAS IKDC Lysholm SF-36 |
[23] |
| Kim et al. (2015) | III | 2 arms | MCS + PRP 71(20) | 94(20) | 24 months | MSC + fibrin glue | Process Protocol | N/R | 1.28 × 106/µL | 1 | IKDC Tegner ICRS |
[28] |
| Lee et al. | I | 2 arms | 24(24) | 25(25) | 24 months | microfracture | Magellan APS (MBTD) | N/R | N/R | 1 | VAS IKDC Lysholm |
[24] |
| Manunta et al. | II | 2 arms | 10 | 10 | 12 months | microfracture | GPS II (Biomet) | N/R | N/R | 3 | VAS IKDC |
[25] |
| Manco et al. | III | 2 arms | 14 | 13 | 24 months | microfracture | Manual | N/R | 0.3–1.5 × 106 | 1 | VAS IKDC SF-36 |
[27] |
| Nguyen et al. | III | 2 arms | 15(15) | 15(15) | 18 months | microfracture | New-PRP Pro Kit (GeneWorld) | N/R | N/R | 1 | WOMAC VAS Lysholm Outerbridge |
[26] |
| Vasavilbaso et al. | I | 5 arms | 10(10) | control 10(10) HA 3 10(10) HA 4 10(10) HA 5 10(10) |
18 months | no injection HA |
GPS II (Biomet) | N/R | N/R | 1 | WOMAC | [22] |
LOE—level of evidence; exp.—no. of patients receiving treatment in experimental group (no. of patients analyzed at final follow-up); cont.—no. of patients receiving treatment in control group (no. of patients analyzed at final follow-up); LR—leukocyte rich; LP—leukocyte poor; ROM—range of movement; BL—blood loss; wound—wound healing; CRP—C reactive protein; HgB—hemoglobin; Ht—hematocrit; PROM—patient related outcome measures; VAS—visual analog scale; WOMAC—Western Ontario and McMaster Universities Osteoarthritis Index; SF-36—36-Item Short Form Survey; Outerbridge—Outerbrige cartilage injury scale; Lysholm—Lysholm Knee Scoring Scale; IKDC—International Knee Documentation Committee.